Nohla Therapeutics Selects Advanced Therapies Business Unit of WuXi AppTec To Manufacture Universal Donor Cell Therapies

SEATTLE and PHILADELPHIA, March 21, 2018 -- Nohla Therapeutics, a leading developer of universal donor cell therapies for patients with hematologic malignances and other critical diseases, and WuXi AppTec Advanced Therapies, a streamlined Contract Development and Manufacturing Organization (CDMO), have entered into a commercial agreement for production of Nohla’s NLA101, a universal donor, ex vivo expanded hematopoietic stem and progenitor cell product.   

“We are excited to partner with WuXi AppTec Advanced Therapies to gain their expertise and cGMP manufacturing capabilities to support the ongoing development and anticipated global commercial demand for our lead cell therapy program, NLA101,” said Katie Fanning, President and Chief Executive Officer of Nohla. 

“We are very pleased to enter into this manufacturing partnership with Nohla,” said Felix Hsu, Senior Vice President and Head of WuXi AppTec Advanced Therapies. “With our integrated manufacturing services, we believe we can bring speed and reliability to the manufacturing needs of Nohla and support the rapid advance of their clinical timelines. We are committed to helping our partners deliver these innovative therapies to patients and the market sooner.” 

WuXi AppTec Advanced Therapies will manufacture Nohla’s universal cell therapies in their 55,000 square foot commercial manufacturing facility for cell therapies, one of three facilities in the Philadelphia Navy Yard supporting the development, manufacturing, and quality control testing of cell and gene therapies. 

About Nohla Therapeutics
Nohla Therapeutics is a clinical stage cell therapy company that’s redefining clinical outcomes for patients with critical diseases by providing a short-term hematopoietic bridge to immune repair and healthy blood production with long-term immunologic benefits. Nohla’s proven platform generates universal, off-the shelf therapies that enable improved clinical outcomes across a number of disease indications, with an initial focus on high-risk hematological malignancies. Nohla's lead candidate, NLA101, is an expanded progenitor cell therapy that provides the functional support of bone marrow in response to each patient’s unique blood-production needs, without any requirement for HLA matching. The product has demonstrated the potential for robust efficacy in multiple clinical trials, while overcoming the broad safety and logistical risks of patient-customized cell therapies. More information is available at www.nohlatherapeutics.com.

About WuXi AppTec
WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost effective and efficient solutions.  The Advanced Therapies business unit of WuXi AppTec is a Contract Development and Manufacturing Organization (CDMO) that reduces the complexities of the high-touch, multi-vendor biopharmaceutical production model by providing platforms that enable cell and gene therapies to be developed, manufactured, and released faster and with greater predictability. Since 2004, WuXi AppTec has supported Advanced Therapy manufacturing programs from their Philadelphia, PA campus which today includes over 220,000 square feet of GMP compliant manufacturing space.  For more information visit http://www.wuxiapptec.com.

Media Contacts:

Nohla Therapeutics
Jim DeNike
Senior Director, Corporate Development & Investor Relations
206.519.5294
[email protected]

WuXi AppTec Advanced Therapies
Jason Noga 
Marketing Manager
215.593.5464
[email protected]